Septerna (NASDAQ:SEPN) COO Sells $149,640.00 in Stock

Septerna, Inc. (NASDAQ:SEPN) COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $37.41, for a total value of $149,640.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares in the company, valued at $6,517,158.69. The trade was a 2.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Elizabeth Bhatt also recently made the following trade(s):

• On Tuesday, August 11th, Elizabeth Bhatt sold 25,000 shares of Septerna stock. The stock was sold at an average price of $44.00, for a total value of $1,100,000.00.

Septerna Stock Up 3.6%

Shares of Septerna stock opened at $40.76 on Thursday. The stock has a market capitalization of $1.90 billion, a P/E ratio of -75.48 and a beta of 2.29. The stock has a 50 day moving average price of $38.93 and a two-hundred day moving average price of $33.88. Septerna, Inc. has a 12-month low of $17.55 and a 12-month high of $51.10.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.14. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. The company had revenue of $26.75 million for the quarter, compared to the consensus estimate of $19.22 million. Sell-side analysts anticipate that Septerna, Inc. will post -1.41 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Stifel Nicolaus set a $49.00 target price on shares of Septerna in a report on Tuesday, August 11th. Raymond James Financial reissued a “strong-buy” rating and set a $49.00 target price on shares of Septerna in a research report on Tuesday, August 11th. HC Wainwright upped their price target on shares of Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. JonesTrading raised their price target on Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research note on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Septerna presently has an average rating of “Moderate Buy” and an average target price of $52.44.

Institutional Investors Weigh In On Septerna

Hedge funds and other institutional investors have recently modified their holdings of the stock. TRV GP V LLC acquired a new position in Septerna during the 2nd quarter valued at $208,160,143. TRV GP VI LLC bought a new stake in Septerna in the 2nd quarter valued at $141,048,460. BlackRock Inc. acquired a new stake in Septerna in the 2nd quarter worth $64,706,000. Jupiter Topco LLC acquired a new stake in Septerna in the 2nd quarter worth $43,723,000. Finally, Primecap Management Co. CA bought a new position in shares of Septerna during the 2nd quarter worth about $39,096,000.

Septerna Company Profile

Septerna, Inc is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in a wide range of biological processes and represent an important source of potential drug targets.

The company’s research is powered by its Native State platform, which is designed to study GPCRs in their natural biological configuration and support the discovery of selective small-molecule compounds.